Group 1 - The core viewpoint of the articles highlights Ruizhi Pharmaceutical's active advancements in the field of small nucleic acid drug research and production, driven by technological innovation and strategic partnerships to enhance its full-chain service capabilities from laboratory to industrialization [1][2] Group 2 - Ruizhi Pharmaceutical, in collaboration with East China Normal University, launched a drug manufacturing system suitable for ADC and nucleotide monomer synthesis, significantly reducing ADC drug process development time by 70% and lowering nucleotide monomer synthesis costs by over 40% [1] - The company has developed hundreds of modified nucleotides, phosphoramidite monomers, and new linkers, leveraging its capabilities in chemical synthesis and early-stage process development [1] - The company is focusing on delivery system efficiency, which is crucial for the successful commercialization of small nucleic acid drugs, by adopting a phased strategy in collaboration with partners like Haiyou Biotechnology [1] - Ruizhi Pharmaceutical is innovatively integrating Corporate Venture Capital (CVC) and AI-driven scientific research (AI4S) into its strategic layout to enhance project selection and build a technological ecosystem [2] - The chairman of Ruizhi Pharmaceutical emphasized that the computational medicine platform of Zheyuan Technology complements CRO services, aiming to unlock the full potential of the industry by identifying effective research directions [2] - The company aims to build differentiated competitive advantages in small nucleic acid drug research through cost reduction and efficiency improvements, breakthroughs in delivery technology, and expanded applications via full-cycle collaborations [2]